Presently, Omnipod 5 is FDA-cleared in the United States and C.E. marked for use in those with type 1 diabetes aged two years and older. More on the Omnipod 5 Study.

Zach White, 23, and Elise Scalfani, 26, open up to PEOPLE about connecting through social media about their shared type 1 diabetes diagnoses, and how that led to them falling in love despite ...

Insulet has announced that its Omnipod 5 Automated Insulin Delivery System has been cleared by the US Food and Drug Administration (FDA) for the indication of type 2 diabetes. The company says ...

Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above).

ACTON, Mass., June 10, 2025--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible ...

Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older.

The bulk of the company’s earnings—nearly $1.25 billion—came from Omnipod sales, which grew more than 23% compared to the prior year. During a call with investors Thursday afternoon, CEO Jim ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations.

Insulet Corporation PODD reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked a ...

The Omnipod 5 App for iPhone, available in the U.S., offers full control of Omnipod 5 including the ability to bolus, change a Pod, adjust settings, access valuable insights, and more.